Yvonne J. Paterson

faculty photo
Professor of Microbiology
Associate Dean, Postdoctoral Training, School of Medicine
Director of Biomedical Postdoctoral Program, University of Pennsylvania
Member, University of Pennsylvania Trustees Committee on Facilities
Member, School of Medicine Lab Programming for Pennsylvania Hall Research Building
Member, University Council Committee on Diversity and Equity
Department: Microbiology

Contact information
323 Johnson Pavilion
3610 Hamilton Walk
Philadelphia, PA 19104-6076
Office: (215) 898-3461
Fax: (215) 573-4666
Graduate Group Affiliations
Education:
B.Sc. (Biochemistry)
University of Manchester, 1963.
M.Sc. (Biochemistry)
University of Manchester, 1966.
B.A. (Mathematics /Philosophy)
Australian National University, 1969.
Ph.D. (Biochemistry, Thesis supervisor: Dr. S. J. Leach)
Melbourne University, 1979.
Permanent link
 

Description of Research Expertise

Research Interests
Rational approaches to immune intervention in neoplastic and infectious disease.

Key words: Immune regulation, antigen design, vaccine development, cancer immunotherapy, HIV, HPV.

Description of Research
The research performed in the Paterson laboratory is dedicated to harnessing the immune system to provide cures for, or protection against, neoplastic and infectious disease. There have been enormous advances made in the last few years in our understanding of the molecular and cellular machinery that renders proteins immunogenic. In our laboratory, we are applying this knowledge to the development of strategies to enhance the immune response in the design of more effective vaccines against viral diseases, such as HIV, and against tumor cells. To do this we are using a facultative intracellular bacterium, Listeria monocytogenes, which has the unusual ability to live and grow in the cytoplasm of the cell. Our laboratory was the first to show that this bacterium could be used to target antigens to the MHC class I pathway for antigen processing with the induction of cytotoxic T cells and has pioneered the application of this organism in vaccine development over the past 15 years. We have shown that recombinant forms of this organism which have been transformed to express viral antigens from influenza, HIV and SIV are excellent vectors for inducing cell mediated immune responses both parenterally and at mucosal surfaces. We have also applied this technology in the development of cancer vaccines that result in the induction of potent cell mediated immunity that can eliminate established macroscopic tumors even in the face of profound immune tolerance to the tumor-associated antigen. In other studies, we have discovered that fusing an antigen to some bacterial proteins enhances its immunogenicity. This finding opens up novel, and perhaps safer, avenues to cancer immunotherapy. We are currently looking at a number of different approaches to carry these fusion proteins to the immune system for cancer immunotherapy. Cancers to which we are directing our various technologies currently include cervical cancer, breast cancer, lung cancer, melanoma and lymphoma.

Rotation Projects for 2006-2007
1. The role of the Listeria’s hemolysin in initiating a protective immune response.
2. Mechanisms of CTL Tumor Infiltration.
3. Listeria based vaccines targeting HER-2/neu for cancer.

Lab personnel:
Anita Giacone - Administrative Coordinator
Paulo Maciag - Postdoctoral Fellow
Elwaleed Mustafa - Postdoctoral Fellow
Zhen-Kun Pan - Research Specialist
Xiaohui Peng - Lab Manager
Marianne Rosario - Lab Assistant
Reshma Singh - Graduate Student
Nick Souders - Graduate Student

Description of Itmat Expertise

Dr. Paterson's research efforts are dedicated to harnessing the immune system to provide cures for, or protection against, neoplastic and infectious disease.

Selected Publications

Mustafa, W., Maciag, P. C., Pan, Z.-K., Weaver, J. R., Xiao, Y., Isaacs, S. N., and Y. Paterson.: Listeria monocytogenes delivery of HPV-16 major capsid protein, L1, induces systemic and mucosal cell-mediated CD4+ and CD8+ T cell responses after oral immunization. Viral Immunology 22: 195-204, 2009.

Wallecha, A., Maciag, P.C., Rivera, S., Paterson, Y., Shahabi V.A.: Construction and characterization of an attenuated Listeria monocytogenes cancer immunotherapeutic for clinical use. Clinical and Vaccine Immunology 16: 96-103, 2009.

Seavey, M.M., Pan, Z.-K., Maciag, P.C., Wallecha, A., Rivera, S., Paterson, Y., Shahabi, V. : A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8+ T cell responses and impact the growth and spread of Her-2/neu+ breast tumors. Clinical Cancer Research 15: 924-932, 2009.

Kim, S. H., Castro, F., Paterson, Y. and Gravekamp, C.: High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Research In Press, 2009.

Seavey, M.S., Maciag, P.C., Al-Rawi, N., Sewell, D. A. and Y. Paterson.: An Anti-VEGFR2/Flk-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the treatment of primary and metastatic Her-2/neu Positive Breast tumors in a mouse model. J. Immunol. 182: 5537-5546, 2009.

Sewell, D.A., Pan, Z.-K., and Y. Paterson. : Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008.

Shahabi, V., Reyes-Reyes, M., Wallecha, A., Rivera, S., Paterson, Y., and P.C. Maciag. : Development of a Listeria monocytogenes Based Vaccine against Prostate cancer. Cancer Immunol. Immunother. In press, 2008.

Maciag, P.C., Seavey, M.M., Pan, Z.-K., Ferrone, S. and Y. Paterson. : Cancer immunotherapy targeting the HMW-MAA protein results in a broad anti-tumor response and reduction of pericytes in the tumor vasculature. Cancer Research 2008.

Kim, S.H., Francisco Castro, F., Diana Gonzalez, D., Maciag, P.C., Paterson, Y., and C. Gravekamp. : Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br. J. Cancer. 2008.

Singh R. and Y. Paterson: In the FVB/N HER-2/neu Transgenic Mouse both Peripheral and Central Tolerance Limit the Immune Response Targeting HER-2/neu Induced by Listeria monocytogenes-based Vaccines. Cancer Immunol. Immunother.(56), 927 - 938, 2007.

back to top
Last updated: 06/05/2009
The Trustees of the University of Pennsylvania